CCNB1 and gastric cancer: In recent years, increasing number of studies have reported that the expression of cyclin B1 may be correlated with the poor outcome of patients with various cancers, including breast carcinoma [8], prostatic cancer [9], pancreatic malignancy [10], lung carcinoma [11], laryngeal cancer [12] as well as hepatocellular cancer [13], gastric cancer (GC) [14–17], colorectal cancer [18–21] and esophageal cancer (EC) [22–25].